This article is published in the Journal of Labelled Compounds and Radiopharmaceuticals as a special issue on ‘Current Developments in PET and SPECT Imaging’, edited by Jonathan R. Dilworth, University of Oxford and Sofia I. Pascu, University of Bath.
Special Issue Review
Imaging COX-2 expression in cancer using PET/SPECT radioligands: current status and future directions†
Article first published online: 18 DEC 2013
Copyright © 2013 John Wiley & Sons, Ltd.
Journal of Labelled Compounds and Radiopharmaceuticals
Special Issue: Current Developments in PET and SPECT Imaging
Volume 57, Issue 4, pages 317–322, April 2014
How to Cite
Pacelli, A., Greenman, J., Cawthorne, C. and Smith, G. (2014), Imaging COX-2 expression in cancer using PET/SPECT radioligands: current status and future directions. J Label Compd Radiopharm, 57: 317–322. doi: 10.1002/jlcr.3160
- Issue published online: 16 APR 2014
- Article first published online: 18 DEC 2013
- Manuscript Accepted: 29 OCT 2013
- Manuscript Received: 9 JUL 2013
- imaging biomarker
The role of cyclooxygenase (COX)-2 as a driving force in early tumourigenesis and the current interest in the combination of COX-2 inhibitors with standard therapy in clinical trials creates an urgent need to establish clinically relevant diagnostic tests for COX-2 expression. Molecular imaging using small-molecule probes radiolabelled for both positron emission tomography (PET) and single photon emission computed tomography (SPECT) offers the potential to meet this need, providing a minimally invasive readout for the whole disease burden. This review summarises current approaches to the radiolabelling of small-molecule COX-2 inhibitors and their analogues for PET and SPECT imaging, and gives an overview of their biological evaluation and likely success of clinical application.